Depressive Disorder, Treatment-Resistant
54
11
13
26
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Published Results
12 trials with published results (22%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
5.6%
3 terminated out of 54 trials
89.7%
+3.1% vs benchmark
17%
9 trials in Phase 3/4
46%
12 of 26 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 26 completed trials
Clinical Trials (54)
NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits
Improving Brain Stimulation Through Imaging
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression
rTMS With and Without Text4Support for the Treatment of Resistant Depression.
Adaptive tDCS for Treatment-Resistant MDD
Dopaminergic Dysfunction in Late-Life Depression
Accelerated vs. Conventional Theta Burst Stimulation for Late-life Depression
NESBID: Neuro-Stimulation of the Brain in Depression
Effects of a Classic High-frequency rTMS Treatment Versus a Deep rTMS Treatment
Intravenous Ketamine for Treatment-Resistant Depression
Behavioural Activation Therapy and Esketamine for Resistant Depression
Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression
Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)
Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression.
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression